Case Report Severe Acute Hepatitis B in HBV-Vaccinated Partner of a Patient with Multiple Myeloma Treated with Cyclophosphamide, Bortezomib, and Dexamethasone and Autologous Stem Cell Transplant by Majed M Almaghrabi et al.
Case Report
Severe Acute Hepatitis B in HBV-Vaccinated Partner of
a Patient with Multiple Myeloma Treated with
Cyclophosphamide, Bortezomib, and Dexamethasone and
Autologous Stem Cell Transplant
Majed M. Almaghrabi,1 Kyle J. Fortinsky,2 and DavidWong2
1Division of Internal Medicine, University of Toronto, Toronto, ON, Canada
2Division of Hepatology, University of Toronto, Toronto, ON, Canada
Correspondence should be addressed to David Wong; dave.wong@uhn.ca
Received 30 January 2017; Accepted 6 March 2017; Published 27 March 2017
Academic Editor: Mauro Vigano
Copyright © 2017 Majed M. Almaghrabi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Hepatitis B reactivation can occur with various forms of immunosuppression. Cyclophosphamide, Bortezomib, and Dexametha-
sone (CYBOR-D) chemotherapy is commonly used for the treatment of multiple myeloma and has not been noted in guidelines to
be causative in HBV reactivation. Indeed, current guidelines do not recommend providing antiviral prophylaxis to patients with
prior HBV infection. We present a case of HBV reactivation as a result of CYBOR-D and autologous stem cell transplant which is
complicated by the patient’s partner who developed acute hepatitis B. Our case highlights the need to review the role of antiviral
prophylaxis for patients undergoing treatment of multiple myeloma and also the role of ensuring immunity for close contacts of
these patients who may also be at risk.
1. Introduction
The natural history of chronic hepatitis B virus (HBV)
infection is characterized by various stages that are influenced
by the host immune response. Resolved HBV infection is
defined by undetectable levels of HBV proteins (HBsAg) and
viral load (HBV DNA) in a patient with evidence of previous
exposure (positive anti-HBc) [1, 2]. HBV reactivation occurs
most often in patients with resolved HBV infection who are
exposed to profound immunosuppression. Current guide-
lines describe certain high-risk patients who may benefit
from antiviral therapy as prophylaxis against HBV reactiva-
tion including those with certain forms of cancer or those on
specific chemotherapeutic agents [3, 4]. However, the guide-
line recommendations are largely based upon expert opinion.
Multiple myeloma (MM) is a cancer resulting in mono-
clonal expansion of IgG against one epitope potentially at the
expense of immunity to other antigens such as HBV. While
the precise mechanism within the host immune response is
largely unknown, recent studies suggest that T-cells may not
be the major players in the natural history of chronic HBV
infection [5]. Importantly, since therapies targeted against
CD20 can result in HBV reactivation even after HBsAg loss,
this suggests that B-lymphocytes and plasma cells likely play
a role in immunity against HBV infection [6]. In patients
undergoing autologous stem cell transplant (ASCT), host
immunity is presumably restored immediately after che-
moablation of cancer cells [7]. Moreover, HBV immunity
can be adoptively transferred in allogeneic bone marrow
transplants. For example, the marrow from a donor who has
immunity to HBV can result in HBsAg clearance in a recip-
ient with chronic HBV infection [8]. Conversely, marrow
from a donor without immunity to HBV can result in HBsAg
recurrence in a recipient who had prior HBV infection that
resolved [9].
A few recent studies have reported cases of HBV reactiva-
tion in patients withMMbeing treated with Bortezomib-based
chemotherapy [10, 11]. Tsukune et al. reported 9 patients
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with MM who received Bortezomib-based chemotherapy
and developed HBV reactivation [12]. Lee et al. reported 12
patents with MM who all received ASCT (2 of whom were
on Bortezomib therapy) and all developed HBV reactivation
[13].
The HBV serological status and the type of immunosup-
pressive therapy are the major determinants in the current
guidelines for prevention and treatment of HBV in patients
undergoing immunosuppressive therapy. Patients who are
HBsAg positive/anti-HBc positive or HBsAg negative/anti-
HBc positive undergoing immunosuppressive therapy with
B-cell depleting agents, anthracycline derivatives, tyrosine
kinase inhibitors, cytokine inhibitors, or integrin inhibitors
are recommended to receive antiviral prophylaxis as they are
considered to be atmoderate to high risk of HBV reactivation
[3]. Proteosome inhibitors (e.g., Bortezomib) are not men-
tioned in the guidelines which suggests they do not require
antiviral prophylaxis. Neither the product monograph for
Bortezomib nor FDA safety labeling mentions a risk of hep-
atitis B reactivation. Additionally, current guidelines do not
mention screening familymembers or household contacts for
immunity against HBV even when patients themselves are at
high risk of HBV reactivation.
The current report describes a case whereby HBV immu-
nity was maintained after the diagnosis of multiple myeloma
but was subsequently lost after chemotherapy and autolo-
gous stem cell transplant. The current case report adds to
the increasing body of literature that suggests Bortezomib-
based chemotherapy regimensmay lead to HBV reactivation.
Importantly, our case is the first report published on acute
hepatitis B in a family member of a patient who develops
HBV reactivation despite a history of HBV vaccination. Our
case highlights important considerations in the management
of patients who are undergoing immunosuppressive therapy
and their families.
2. Case 1
A 68-year-old Canadian man, originally born in Italy, was
referred to our hepatology clinic for management of HBV
reactivation after his wife was diagnosed with acute HBV
(see Case 2 for details of wife). He was diagnosed with MM
andwas treated with five cycles of Cyclophosphamide, Borte-
zomib, and Dexamethasone (CYBOR-D) prior to undergo-
ing an autologous stem cell transplant (ASCT). After the
transplant, he was put on Lenalidomide for maintenance
therapy. Prophylactic HBV antiviral therapy was not given.
His past medical history was remarkable only for resolved
HBV infection (HBsAg negative, anti-HBc positive, and anti-
HBs positive), which was noted prior to transplantation.
After CYBOR-D chemotherapy, anti-HBs became nega-
tive and ALT was elevated. In February 2013 his anti-HBs
was positive and inDecember 2014 his anti-HBs was found to
be negative. In February 2016, his family physician provided
HBV vaccination presumably because he was unaware of his
prior HBV infection. Testing for HBV reactivation was not





























































































































Figure 1: Liver enzymes andHBV tests in relation to chemotherapy,
autologous stem cell transplant, and entecavir therapy.
Once his wife was diagnosed with acute HBV, he was
diagnosed with HBV reactivation: HBsAg positive (titer >
124,925 IU/mL),HBeAgpositive,HBVDNA> 1.70E8 IU/mL,
and ALT persistently normal. His anti-HCV was negative
and he remained immune to hepatitis A. In retrospect, liver
enzymes had been abnormal (ALT peak 182) during the HBV
vaccination period but were normal when his wife presented
with acute hepatitis (see Figure 1). An abdominal ultrasound
was unremarkable and a FibroScan was consistent with F1
(minimal) fibrosis. He was started immediately on entecavir
for HBV reactivation.
At 4 months’ follow-up, he remained asymptomatic from
a liver perspective. His liver enzymes and liver function were
normal and his HBV viral load was reduced to 4.64E4 IU/mL
on entecavir.
3. Case 2
A 68-year-old Canadian woman, originally born in Canada,
was admitted to hospital for 2 days after developing jaundice
and severe fatigue over the past two weeks. Her past medical
history was significant for osteoarthritis, where she was
taking daily acetaminophen (<2 grams per day). She denied
any sick contacts, recent travel, or symptoms suggestive of
an underlying autoimmune disorder. She denied taking any
additional medications or herbal supplements. She was a
nonsmoker and denied any alcohol or illicit drug use. She
had no prior blood transfusions, tattoos, needle stick injuries,
incarceration, or recent travel to an HBV endemic country.
She reported receiving prior immunization to hepatitis B in
1988 prior to a trip to India but had not been tested for
adequate anti-HBs levels.
On examination, she was afebrile and hemodynamically
stable. She appeared jaundiced but therewere no signs of hep-
atic encephalopathy. Liver edge was mildly tender and palpa-
ble, 4 cmbelow the costalmargin.Therewas no splenomegaly,
ascites, or other stigmata of chronic liver disease. She had no
rashes or arthritis.The remainder of her physical examination
was unrevealing.
Blood tests showed marked transaminitis (see Figure 2),
INR 1.3, and Bilirubin up to 411 umol/L. HBV serology was










































































Figure 2: Liver enzymes and HBV tests in relation to entecavir
therapy.
consistent with an acute HBV infection as evidenced by
a positive IgM anti-HBc, HBsAg, and HBeAg. Abdominal
ultrasound revealed an enlarged liver that was 14.8 cm but
was otherwise unremarkable. She was treated with entecavir
for symptomatic acute HBV infection and her fatigue mostly
resolved after a week of therapy.
At 4 months’ follow-up, the patient was feeling well, and
her liver enzymes and liver function were normal. Her viral
loadwas undetectable andherHBsAgwas negative indicating
successfully cleared infection; entecavir therapy was stopped.
4. Discussion
Most cases of HBV reactivation in the literature describe
HBsAg seroreversion that leads to either low-level viremia
without ALT elevation or more significant reactivation with
high-level viremia and ongoing immune-mediated liver
injury with ALT elevation. Interestingly, our patient in Case 1
developed HBsAg seroreversion with only transient hepatitis
before entering what looked like the immune tolerant phase.
There have only been 2 previous reported cases of patients
with MM who received Bortezomib and had HBV reactiva-
tion followed directly by an immunotolerant phase [10, 11].
The precise role of antiviral prophylaxis in patients with
resolved HBVwho are undergoing ASCT remains controver-
sial [3, 4, 13]. Tsukune et al. recommend serial monitoring of
HBsAg or HBV DNA as a strategy to detect reactivation [12].
There do appear to be certain risk factors for HBV. Patients
with negative anti-HBs seem to be at higher risk of HBV
reactivation when compared to patients with a positive anti-
HBs [13].
It is interesting to note that the patient’s wife developed
acute hepatitis B several months after we suspect the patient
developed reactivation. Unfortunately, despite a rise in our
patient’s liver enzymes after ASCT, he was not recognized to
have reactivation until his wife developed acute HBV. The
delay between reactivation and his wife’s acute HBV infection
may be attributable to a rising HBV DNA level during that
period as he was becoming more infectious.
There may have been several factors contributing to
our patients HBV reactivation including Cyclophosphamide,
Bortezomib, Dexamethasone, ASCT, and Lenalidomide ther-
apy. Lenalidomide is a potent immunomodulator and T-cell
stimulator. It has been recommended to be used with caution
in patients infectedwithHBV, though the role of immunomo-
dulators inHBV reactivation is still undetermined [14]. ASCT
has also been raised as a risk factor for HBV reactivation
[15]. Bortezomib, a proteasome inhibitor, has been previ-
ously reported in a few cases of HBV reactivation in MM
patients [10, 11]. Given its mechanism of action, Bortezomib
may impair intracellular viral antigen processing leading to
impaired maintenance of T-cell memory [16]. Recent guide-
lines, however, do not acknowledge that HBV reactivation
might occur in patients exposed to Bortezomib therapy [3, 4].
Lastly, there is evidence that systemic corticosteroids such
as Dexamethasone may also increase the risk of reactivation
[17].
Interestingly, our patient lost anti-HBs, which prompted
his family physician to repeat vaccination instead of testing
for HBV reactivation. There are no data to support the
strategy of HBV vaccination in those who lose anti-HBs after
immunosuppression. Although patients with a negative anti-
HBs may be at higher risk for reactivation compared to
patients with a positive anti-HBs, current guidelines do not
suggest prophylaxis for patients based upon their anti-HBs
status alone. In general, prophylaxis with HBV antiviral ther-
apy is initiated at the beginning of chemotherapy until approx-
imately 6months after completing therapy.Moreover, current
guidelines do not recommend routine testing for family
members or close contacts of patients at risk for reactivation.
The majority of patients with acute hepatitis B recover
spontaneouslywithout need for antiviral treatment.However,
those who have symptomatic acute HBV infection may ben-
efit from antiviral therapy to shorten duration and severity
of symptoms. Those who remain HBeAg positive with high-
level viremia more than 3 months after infection may benefit
from antiviral therapy to prevent establishment of chronic
infection. In regard to treatment, there are different choices
of antiviral therapies including lamivudine, tenofovir, and
entecavir [18].
This report highlights a case of HBV reactivation in
a patient with MM treated with Bortezomib containing
chemotherapy. It is still unclear if antiviral therapy versus
careful monitoring is the best strategy for such patients. As
the risk of reactivation is low and can take place over many
years [12], it may be reasonable to monitor HBsAg every 6
months for 3 to 5 years after therapy rather than treating all
with antivirals for 5 years.
Our case described a unique situation where the patient
lost anti-HBs and vaccination did not prevent reactiva-
tion. Clinicians should consider more careful monitoring of
patients undergoing Bortezomib-based chemotherapy and
pay especially close attention to patients without anti-HBs.
HBV vaccination in those who lose anti-HBs should not
be undertaken until HBsAg testing to rule out HBV reacti-
vation has been done. Furthermore, testing to monitor for
HBV reactivation should be performed routinely during and
immediately after treatment. Lastly, our case describes an
unusual complication of a family member developing acute
HBV as a result of reactivation in her husband.This occurred
4 Case Reports in Hepatology
despite the wife being vaccinated many years priorly. The
authors suggest that clinicians consider screening close
household contacts of patients at risk for HBV reactivation
in order to identify those without immunity to HBV who
could benefit from repeat vaccination. Our cases portray
the importance of considering both the patient and family
members or close contacts who can also be adversely affected
by medical treatments.
Consent
Informed consent was obtained from both patients in the
publication of this case report as per hospital policy.
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